Jefferies raised the firm’s price target on AstraZeneca to 11,700 GBp from 11,300 GBp and keeps a Hold rating on the shares. The firm’s Q2 revenue forecast is 2% below consensus, though it thinks that the 2024 outlook may be upgraded to low-mid teens growth for revenue and EPS, the analyst tells investors in a preview note for the EU pharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s MAA for sipavibart accepted by EMA for COVID-19 prevention
- AstraZeneca’s Imfinzi, Lynparza recommended for approval in EU by CHMP
- AstraZeneca says Tagrisso with addition of chemo approved in China for NSCLC
- UK Stocks: AstraZeneca’s (AZN) Imfinzi Disappoints in Advanced Lung Cancer Trial
- AstraZeneca’s Imfinzi demonstrated statistically significant improvement